- Spectral Medical (EDT) announced two new clinical trial sites to support its Tigris trial evaluation of its Toraymyxin candidate for septic shock treatment
- One trail site will take place at the Medical University of South Carolina, and the other will be at the University of California San Francisco
- The addition of these sites will bring the number of clinical Tigris trials to 16 active sites
- The candidate product is a device that removes endotoxin, which can cause sepsis, from the bloodstream and works alongside the company’s endotoxin activity assay
- Spectral Medical (EDT) is up 3.33 per cent, trading at $0.31 per share as of 2:31 p.m. EST
Spectral Medical (EDT) announced two new clinical trial sites to support its Tigris trial evaluation of its Toraymyxin candidate for septic shock treatment.
One trail site will take place at the Medical University of South Carolina (MUSC), and the other will be at the University of California San Francisco. The addition of these sites will bring the number of clinical Tigris trials to 16 active sites.
“We are pleased to add two additional excellent clinical trial sites for Tigris, which is expected to accelerate patient enrollment and enable us to more rapidly reach our 150 total patient target,” CMO of EDT, Dr. John Kellum, said.
“With no approved or cleared treatment on the market to date, we believe, if Tigris is successful, we can swiftly move towards FDA submission and address a significant unmet medical need with a market currently estimated at $2 billion in the United States alone.”
Unique product aiming to be FDA approved
EDT specializes in phase three clinical studies and is seeking U.S. FDA approval for its product, Toraymyxin. The candidate product is a device that removes endotoxin, which can cause sepsis, from the bloodstream and works alongside the company’s endotoxin activity assay.
“We’re already hard at work to identify patients for Tigris,” Dr. Blaithin A. McMahon, Associate Professor of Medicine at MUSC, added. “There is an incredible need for sepsis research because sepsis destroys the lives of many of our patients, and we are quite excited to be on the team.”
According to EDT, the candidate product has been approved for use in Japan and Europe and has been used on more than 340,000 patients to date.
Spectral Medical (EDT) is up 3.33 per cent, trading at $0.31 per share as of 2:31 p.m. EST.
